Drug Information

Drug General Information
Drug ID
D00HYK
Former ID
DIB009549
Drug Name
AFN-1252
Synonyms
API-1252; API-1401; Antibacterial therapeutics, Affinium; Antibacterials, Affinium; Bacterial fatty acid biosynthesis inhibitors, Affinium; Galapagos program, Affinium; Antibacterial therapeutics, Affinium/GSK; Antibacterials, Affinium/GSK; FabI inhibitors (antibacterial), Affinium; AFN-1252 (oral, bacterial infection); AFN-1252 (oral, bacterial infection), Affinium
Drug Type
Small molecular drug
Indication Staphylococcus aureus infection [ICD10:B95.6] Phase 2 [532242]
Company
Affinium pharmaceuticals
Structure
Download
2D MOL

3D MOL
Formula
C22H21N3O3
Canonical SMILES
N(C(=O)/C=C/c1cc2c(nc1)NC(=O)CC2)(Cc1oc2c(c1C)cccc2)C
CAS Number
CAS 620175-39-5
PubChem Compound ID
10407120
Drug Resistance Mutation (DRM)
DRM DRM Info
Target and Pathway
Target(s) Staphylococcus aureus Enoyl ACP reductase Target Info Inhibitor [532242]
KEGG Pathway Fatty acid biosynthesis
Biotin metabolism
Metabolic pathways
Fatty acid metabolism
References
Ref 532242Activity of AFN-1252, a novel FabI inhibitor, against Staphylococcus aureus in an in vitro pharmacodynamic model simulating human pharmacokinetics. J Chemother. 2013 Feb;25(1):32-5.
Ref 532242Activity of AFN-1252, a novel FabI inhibitor, against Staphylococcus aureus in an in vitro pharmacodynamic model simulating human pharmacokinetics. J Chemother. 2013 Feb;25(1):32-5.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.